Status:
WITHDRAWN
A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer which has spread to other parts of the body. This study is seeking participants who: * have lung can...
Eligibility Criteria
Inclusion
- at least 18 years old
- confirmed diagnosis of EGFR mutation-positive NSCLC
- at least one measurable intracranial metastasis
- ECOG-PS of 0, 1 or 2
- dacomitinib as first-line treatment for advanced NSCLC
- Evidence of a personally signed and dated informed consent document (ICD)
Exclusion
- any anti-cancer systemic treatment within 12 months prior to index date
- currently on active investigational drug(s) treatment in other clinical studies (Phase 1-4) within 2 weeks before the current study begins and/or during study participation.
Key Trial Info
Start Date :
September 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 7 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06075615
Start Date
September 30 2024
End Date
September 7 2026
Last Update
February 7 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.